The judgment sends a powerful message about the limits of deceit in heavily negotiated M&A transactions and the high threshold for these types of claims.
Oliver Steeple, Signature Litigation
Principal third-party disclosure mechanisms and the common pitfalls for pharmaceutical compliance and risk teams.